SCHEMBL13080077

SCHEMBL13080077

COCC/C(=C/c1c(Cl)c(OC)c2ccccc2c1OC)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APEX1 P27695 6/20 0.52
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 1/20 0.34
MAPK1 P28482 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
SLC2A1 P11166 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33
IDO1 P14902 1/20 0.33
PTGES O14684 2/20 0.33
ALOX5 P09917 2/20 0.33
DRD2 P14416 1/20 0.32
DRD3 P35462 1/20 0.32
PPARG P37231 1/20 0.32
PTGER4 P35408 1/20 0.32
CCR2 P41597 1/20 0.32
TSHR P16473 1/20 0.32
GLA P06280 1/20 0.32
HPGD P15428 1/20 0.32
LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3806858 1.00 APEX1 (0.52) APEX1KDM4EALDH1A1MAPK1SMN1; SMN2
SCHEMBL3806859 1.00 APEX1 (0.52) APEX1KDM4EALDH1A1MAPK1SMN1; SMN2
SCHEMBL3758331 0.90 APEX1 (0.41) APEX1KDM4EALDH1A1MAPK1SMN1; SMN2
SCHEMBL3758330 0.90 APEX1 (0.41) APEX1KDM4EALDH1A1MAPK1SMN1; SMN2
SCHEMBL13080052 0.90 APEX1 (0.40) APEX1KDM4EALDH1A1MAPK1SMN1; SMN2
SCHEMBL3751223 0.90 APEX1 (0.40) APEX1KDM4EALDH1A1MAPK1SMN1; SMN2
SCHEMBL3751227 0.90 APEX1 (0.40) APEX1KDM4EALDH1A1MAPK1SMN1; SMN2
SCHEMBL3677795 0.86 APEX1 (0.51) APEX1KDM4EALDH1A1MAPK1SMN1; SMN2
SCHEMBL13080092 0.86 APEX1 (0.51) APEX1KDM4EALDH1A1MAPK1SMN1; SMN2
SCHEMBL3677796 0.86 APEX1 (0.51) APEX1KDM4EALDH1A1MAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100297113-A1 QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF PURDUE RESEARCH FOUNDATION 2010-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100297113-A1 QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF APEX1, NQO1, REV1 APEX1 1/4885KDM4E 2642/4885ALDH1A1 210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.